Selected article for: "combination therapy and drug resistance"

Author: Evans, Jilly Frances; Obraztsova, Kseniya; Lin, Susan M.; Krymskaya, Vera P.
Title: CrossTORC and WNTegration in Disease: Focus on Lymphangioleiomyomatosis
  • Cord-id: osmc7x39
  • Document date: 2021_2_24
  • ID: osmc7x39
    Snippet: The mechanistic target of rapamycin (mTOR) and wingless-related integration site (Wnt) signal transduction networks are evolutionarily conserved mammalian growth and cellular development networks. Most cells express many of the proteins in both pathways, and this review will briefly describe only the key proteins and their intra- and extracellular crosstalk. These complex interactions will be discussed in relation to cancer development, drug resistance, and stem cell exhaustion. This review will
    Document: The mechanistic target of rapamycin (mTOR) and wingless-related integration site (Wnt) signal transduction networks are evolutionarily conserved mammalian growth and cellular development networks. Most cells express many of the proteins in both pathways, and this review will briefly describe only the key proteins and their intra- and extracellular crosstalk. These complex interactions will be discussed in relation to cancer development, drug resistance, and stem cell exhaustion. This review will also highlight the tumor-suppressive tuberous sclerosis complex (TSC) mutated, mTOR-hyperactive lung disease of women, lymphangioleiomyomatosis (LAM). We will summarize recent advances in the targeting of these pathways by monotherapy or combination therapy, as well as future potential treatments.

    Search related documents:
    Co phrase search for related documents
    • action mechanism and adaptive design: 1
    • action mechanism and adcs antibody drug conjugate: 1
    • activation inhibition and acute myeloid leukemia: 1
    • adaptive design and add efficacy: 1